222 related articles for article (PubMed ID: 31253543)
1. Disparity in the use of adjuvant radioactive iodine ablation among high-risk papillary thyroid cancer patients.
Moten AS; Zhao H; Intenzo CM; Willis AI
Eur J Surg Oncol; 2019 Nov; 45(11):2090-2095. PubMed ID: 31253543
[TBL] [Abstract][Full Text] [Related]
2. The overuse of radioactive iodine in low-risk papillary thyroid cancer patients.
Moten AS; Zhao H; Willis AI
Surg Oncol; 2019 Jun; 29():184-189. PubMed ID: 31196486
[TBL] [Abstract][Full Text] [Related]
3. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
4. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
[TBL] [Abstract][Full Text] [Related]
5. The impact of radioactive iodine treatment on survival among papillary thyroid cancer patients according to the 7th and 8th editions of the AJCC/TNM staging system: a SEER-based study.
Liu X; Fan Y; Liu Y; He X; Zheng X; Tan J; Jia Q; Meng Z
Updates Surg; 2020 Sep; 72(3):871-884. PubMed ID: 32342347
[TBL] [Abstract][Full Text] [Related]
6. Too Much of a Good Thing: Radioactive Iodine Ablation Use for Micropapillary Thyroid Carcinoma.
Chae AW; Martinez SR
Am Surg; 2018 May; 84(5):637-643. PubMed ID: 29966562
[TBL] [Abstract][Full Text] [Related]
7. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
8. Demographic and socioeconomic factors predictive of compliance with American Thyroid Association guidelines for the treatment for advanced papillary thyroid carcinoma.
Wenaas AE; Nagy CZ; Yiu Y; Xu L; Horter K; Zevallos JP
Head Neck; 2015 Dec; 37(12):1776-80. PubMed ID: 24986680
[TBL] [Abstract][Full Text] [Related]
9. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
10. Association of medicaid expansion of the Affordable Care Act with the stage at diagnosis and treatment of papillary thyroid cancer: A difference-in-differences analysis.
Limberg J; Stefanova D; Thiesmeyer JW; Ullmann TM; Bains S; Finnerty BM; Zarnegar R; Li J; Fahey Iii TJ; Beninato T
Am J Surg; 2021 Sep; 222(3):562-569. PubMed ID: 33541689
[TBL] [Abstract][Full Text] [Related]
11. Changes in Population-Level and Institutional-Level Prescribing Habits of Radioiodine Therapy for Papillary Thyroid Cancer.
Jacobs D; Breen CT; Pucar D; Holt EH; Judson BL; Mehra S
Thyroid; 2021 Feb; 31(2):272-279. PubMed ID: 32811347
[No Abstract] [Full Text] [Related]
12. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
[TBL] [Abstract][Full Text] [Related]
13. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
15. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
16. Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant.
Dai P; Zhao W; Zheng X; Luo H; Wang X
J Clin Endocrinol Metab; 2024 Feb; 109(3):e1260-e1266. PubMed ID: 37804527
[TBL] [Abstract][Full Text] [Related]
17. Practice patterns among thyroid cancer surgeons: implications of performing a prophylactic central neck dissection.
Deutschmann MW; Chin-Lenn L; Nakoneshny SC; Dort JC; Pasieka JL; Chandarana SP
J Otolaryngol Head Neck Surg; 2016 Oct; 45(1):55. PubMed ID: 27793192
[TBL] [Abstract][Full Text] [Related]
18. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
[TBL] [Abstract][Full Text] [Related]
19. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
20. Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage.
Zambeli-Ljepović A; Wang F; Dinan MA; Hyslop T; Roman SA; Sosa JA; Scheri RP
J Surg Res; 2019 Nov; 243():189-197. PubMed ID: 31185435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
